Preclinical Evaluation of JAB-2485, a Potent AURKA Inhibitor with High Selectivity and Favorable Pharmacokinetic...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Aurora kinase A (AURKA) is a key regulator of mitosis and is frequently overactivated in various cancers.
• Targeting AURKA presents a promising therapeutic strategy for solid tumors.

Purpose of the Study:

• To evaluate the preclinical characteristics of JAB-2485, a novel small-molecule inhibitor of AURKA.
• To assess the efficacy and safety profile of JAB-2485 in preclinical cancer models.

Main Methods:

• Biochemical assays were used to determine the potency and selectivity of JAB-2485 against AURKA, AURKB, and AURKC.
• Pharmacokinetic studies evaluated JAB-2485's properties, including clearance and bioavailability.
• In vitro studies assessed JAB-2485's effects on cell cycle arrest, apoptosis, and proliferation in cancer cell lines.
• In vivo studies evaluated JAB-2485's antitumor activity in xenograft models, both as monotherapy and in combination treatments.

Main Results:

• JAB-2485 demonstrated potent and highly selective inhibition of AURKA (subnanomolar IC50, ~1500-fold selectivity over AURKB/C).
• The inhibitor exhibited favorable pharmacokinetics, including low clearance, good bioavailability, and a clear dose-response relationship.
• JAB-2485 effectively induced G2/M cell cycle arrest and apoptosis, inhibiting proliferation in small cell lung cancer, triple-negative breast cancer, and neuroblastoma cells.
• Robust in vivo antitumor activity was observed in xenograft models, both as a single agent and in combination with chemotherapy or JAB-8263.

Conclusions:

• JAB-2485 displays significant preclinical efficacy and a favorable safety profile, including low hematotoxicity and off-target liability.
• These preclinical findings provide a strong rationale for the ongoing clinical evaluation of JAB-2485 in cancer patients.